SANGAMO THERAPUETICS, INC. INDEMNITY AGREEMENTIndemnity Agreement • May 11th, 2020 • Sangamo Therapeutics, Inc • Biological products, (no disgnostic substances) • Delaware
THIS INDEMNITY AGREEMENT (this “Agreement”) dated as of May __, 2020, is made by and between SANGAMO THERAPEUTICS, INC., a Delaware corporation (the “Company”), and [_________________] (“Indemnitee”).
Confidential Execution Version [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange...Confidential Collaboration and License Agreement • May 11th, 2020 • Sangamo Therapeutics, Inc • Biological products, (no disgnostic substances)
STOCK PURCHASE AGREEMENTStock Purchase Agreement • May 11th, 2020 • Sangamo Therapeutics, Inc • Biological products, (no disgnostic substances) • Delaware
THIS STOCK PURCHASE AGREEMENT (“Agreement”) is entered into as of February 26, 2020 (the “Execution Date”), by and between Biogen MA, Inc., a corporation organized under the laws of the Commonwealth of Massachusetts having an office at 225 Binney Street, Cambridge, MA 02142 (“Biogen”), and Sangamo Therapeutics, Inc., a Delaware corporation having an office at 7000 Marina Blvd., Brisbane, CA 94005 (“Sangamo”). The capitalized terms used herein and not otherwise defined have the meanings given to them in Appendix 1.
